Historically, women and girls affected by hemophilia have experienced protracted delays in securing an accurate diagnosis and care that takes bleeding disorders into full account. A newly published paper takes a 200+ year view of this history and provides a better understanding of just how this underserved population has slowly but surely garnered greater visibility and awareness – if not equitable care – over the decades. 

Roche (and Roche group member Chugai) recently presented data from a phase I/II clinical study of their investigational bispecific antibody therapy NXT007, in people with hemophilia A who do not have factor VIII inhibitors. NXT007 is being positioned as a next-generation subcutaneous prophylactic treatment that builds on the technology used to develop emicizumab (Hemlibra®). 

Pathway to Cures’ investment in Spark Biomedical is an example of how we foster the development of innovative approaches to healthcare access and unmet medical needs in the blood and bleeding disorders community.

The National Bleeding Disorders Foundation (NBDF) is delighted to announce a new accredited education opportunity for health care providers focused on personalized care for individuals with von Willebrand disease (VWD).

“Restoring Control in von Willebrand Disease: Collaborative Approaches for Delivering the Right Treatment for the Right Patient at the Right Time,” is an enduring activity planned and implemented by the PeerView Institute (PVI) for Medical Education and NBDF.